Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Entrada Therapeutics, Inc. (TRDA)
Company Research
Source: GlobeNewswire
-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year -- BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight patients who completed dosing in Cohort 1 of the double-blinded, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-44-201. The DMC recommended initiation of Cohort 2 at 12 mg/kg, a dose escalation from 6 mg/kg in Cohort 1. ELEVATE-44-201 is a Phase 1/2 MAD clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. “We are pleased that after reviewing the Cohort 1 data from our ELEVATE-44-201 study, the independent
Show less
Read more
Impact Snapshot
Event Time:
TRDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRDA alerts
High impacting Entrada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRDA
News
- Entrada Therapeutics (NASDAQ:TRDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study [Yahoo! Finance]Yahoo! Finance
- Entrada Therapeutics (NASDAQ:TRDA) was upgraded by analysts at Guggenheim to a "strong-buy" rating.MarketBeat
- Entrada Therapeutics (NASDAQ:TRDA) was given a new $20.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock.MarketBeat
- Entrada Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
TRDA
Earnings
- 11/6/25 - Miss
TRDA
Sec Filings
- 1/8/26 - Form 8-K
- 12/4/25 - Form EFFECT
- 11/25/25 - Form SCHEDULE
- TRDA's page on the SEC website